Health · NYSE ARCA · USD · Data as of 2026-07-30
AUM
$86.78M
Expense ratio
0.34%
Yield
0.00%
YTD return
+20.89%
Last price
$96.70
Thematic Sector · Coverage 100% · medium
Today
49.6
Outlook
50.9
Block A (composite-derived)
52.5
Block C (market behavior)
48.8
Today overlay (Block D)
0.0
Outlook overlay (Block D)
0.0
today_score = clip(0,100, 50 + 0.15·(A−50) + 0.60·(C−50) + D_today). Block B (holdings rollup) is in Phase 3 development; β=0 caps the natural range at ~12.5–87.5 in Preview v0.9. Formula version tide-etf-v1.0.0.
52.5
Coverage 100% · high
Liquidity
34.4
Expenses
80.0
Performance
56.6
Volatility
20.6
Dividend
2.9
Concentration
70.0
Smart Money
65.9
Activist
98.5
Formula version composite-v1.0.0. Axes hover to see why a sub-score is missing.
Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund from Virtus in the Mixed asset class. Launched in 2014. Assets under management: 59,285,992.
Bullish Whales composite rating: 52 out of 100. Evidence coverage 100% across 8 of 8 axes. Strongest axes: activist exposure, expenses, concentration.
Annualized one-year realized volatility 24%, classified high. Weakest axes: dividend, volatility.
Top-10 weight 0%, diversified, led by IBRX.
etf_composite_score_current · activist_score, composite_score, concentration_score, confidence, coverage_pct, dividend_score, expenses_score, volatility_scoreetf_holdings_top10 · holding_symbol, weightetf_universe · asset_class, aum_usd, fund_type, inception_date, issuer, name, ticker, volatility_1yVirtus LifeSci Biotech Products ETF is an exchange-traded fund that primarily focuses on companies in the biotechnology sector. This ETF aims to provide investment results that correspond to the performance of the LifeSci Biotechnology Products Index, which includes firms heavily involved in the development, testing, and commercialization of novel pharmaceuticals and biological products. In the financial market, it serves as an important tool for investors seeking exposure to the innovative biotechnology field, which impacts sectors such as healthcare, pharmaceuticals, and life sciences. Virtus LifeSci Biotech Products ETF assists in diversifying investments in a rapidly evolving industry by including companies of various sizes and stages, from established biotechnology firms to emerging startups. Its significant role is reflected in its ability to capture the growth and advancements in biotech innovations, ultimately contributing to broader market insights on cutting-edge medical therapies and technologies.
30-day change
$8.86M
90-day change
—
Current AUM: $86,779,832. AUM change is computed from rolling daily fundamentals snapshots; it reflects total net-asset deltas (creations/redemptions + market value moves), not pure share creations.
Fund documents (fact sheets, prospectuses, semi-annual reports) for BBP are coming soon. The BW fund-document archive will surface PDFs alongside a metadata index for searchability.